- Home
- ADPT vs GAM Comparison
ADPT vs GAM Comparison
Compare ADPT & GAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADPT
- GAM
- Stock Information
- Founded
- ADPT 2009
- GAM 1927
- Country
- ADPT United States
- GAM United States
- Employees
- ADPT N/A
- GAM N/A
- Industry
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- GAM Investment Managers
- Sector
- ADPT Health Care
- GAM Finance
- Exchange
- ADPT Nasdaq
- GAM Nasdaq
- Market Cap
- ADPT 1.4B
- GAM 1.2B
- IPO Year
- ADPT 2019
- GAM N/A
- Fundamental
- Price
- ADPT $9.53
- GAM $54.25
- Analyst Decision
- ADPT Buy
- GAM
- Analyst Count
- ADPT 6
- GAM 0
- Target Price
- ADPT $9.83
- GAM N/A
- AVG Volume (30 Days)
- ADPT 2.5M
- GAM 20.1K
- Earning Date
- ADPT 05-01-2025
- GAM 01-01-0001
- Dividend Yield
- ADPT N/A
- GAM 5.74%
- EPS Growth
- ADPT N/A
- GAM N/A
- EPS
- ADPT N/A
- GAM 11.67
- Revenue
- ADPT $189,527,000.00
- GAM N/A
- Revenue This Year
- ADPT $25.00
- GAM N/A
- Revenue Next Year
- ADPT $20.38
- GAM N/A
- P/E Ratio
- ADPT N/A
- GAM $3.95
- Revenue Growth
- ADPT 8.61
- GAM N/A
- 52 Week Low
- ADPT $2.99
- GAM $37.32
- 52 Week High
- ADPT $10.28
- GAM $46.48
- Technical
- Relative Strength Index (RSI)
- ADPT 59.79
- GAM 64.08
- Support Level
- ADPT $8.50
- GAM $53.55
- Resistance Level
- ADPT $9.69
- GAM $54.46
- Average True Range (ATR)
- ADPT 0.41
- GAM 0.72
- MACD
- ADPT -0.01
- GAM -0.01
- Stochastic Oscillator
- ADPT 77.52
- GAM 70.27
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
About GAM General American Investors Inc.
General American Investors Co Inc is a closed-end, diversified management investment company. The primary investment objective of the company is long-term capital appreciation through investment in companies with above-average growth potential. It focuses on equity securities with growth potential at reasonable valuations.